Analyst Price Targets — PRME
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 7, 2024 8:07 am | Maury Raycroft | Jefferies | $15.00 | $5.40 | TheFly | Prime Medicine assumed with a Buy at Jefferies |
| April 2, 2024 4:15 pm | David Nierengarten | Wedbush | $12.00 | $6.32 | TheFly | Prime Medicine initiated with a Buy at Wedbush |
| October 9, 2023 2:19 pm | Kostas Biliouris | BMO Capital | $19.00 | $8.75 | Benzinga | Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: Analyst |
| November 14, 2022 6:19 am | — | Morgan Stanley | $23.00 | $21.12 | Benzinga | Morgan Stanley Initiates Coverage On Prime Medicine with Equal-Weight Rating, Announces Price Target of $23 |
Latest News for PRME
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Svetlana Makhni as Chief Financial Officer (CFO).
MONTRÉAL, April 14, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces a non-brokered private placement (the “Private Placement”) of a minimum of 10 units (each, a “Unit”) and a maximum of 16 Units at a price of $250,000 per Unit, for minimum and maximum gross proceeds of $2,500,000 and $4,000,000, respectively.
Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability. Risk and Volatility Prime Medicine has a
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends. Earnings and Valuation This table compares Athira
Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability. Analyst Ratings This is a summary of
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRME.
U.S. House Trading
No House trades found for PRME.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.